HSIC
Henry Schein
$78.67
▼ 1.6%Updated Jun 22, 7:15 PM ET
▲ Up 12.4% over the last 12 months
Market Cap
$9.10B
P/E
23.08x
Forward P/E (est.)
22.43x
ROE
11.9%
Revenue Growth
5.6%
EPS Growth
2.9%
Profit Margin
3.0%
FCF Yield
6.3%
Debt / Equity
0.96x
ROIC
12.0%
Interest Coverage
4.35x
Current Ratio
1.36x
Dividend Yield
—
Implied Growth (rev. DCF)
2.5%
Rating Score
46/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what HSIC's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. HSIC trades near $78.67, above its 50-day average ($75.71) and 200-day average ($73.60). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 67 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. HSIC's is $1.76 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month HSIC found buyers near $71.66 (support) and sellers near $82.31 (resistance); its 52-week range is $61.95–$89.29. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Henry Schein (HSIC) is a mid-cap company in the Health Care Distributors industry, part of the Health Care sector of the S&P 500, with a market value around $9.10B.
In its latest reported year it generated about $13.18B in revenue and $398.00M in net profit.
Our model rates HSIC Neutral (46/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
1.5%
Revenue moved from $12.40B in 2021 to $13.18B in 2025, a 1.5% compound annual growth rate. The most recent year grew a steady 5.6% year over year. Slower, mature growth is common for established businesses.
Gross Margin
31.1%
Operating Margin
5.0%
Net Margin
3.0%
ROE
11.9%
Henry Schein keeps about 3.0% of each sales dollar as net profit, with a 31.1% gross margin and 5.0% operating margin. Return on equity is 11.9% and return on invested capital about 12.0%. Thin margins leave less cushion if costs rise.
Total Debt
$1.05B
Net Debt
$957.88M
Net Debt / EBITDA
1.47x
Debt / Equity
0.96x
Leverage: debt-to-equity is 1.0x, and operating profit covers interest about 4.3x, with a current ratio of 1.4x. That is a moderate, manageable debt load for most businesses. It carries roughly $1.05B of total debt against $88.11M of cash.
Operating CF
$712.00M
Free Cash Flow
$573.00M
FCF Margin
4.3%
In the latest year Henry Schein produced about $712.00M of operating cash flow and $573.00M of free cash flow after capital spending. That is a free-cash-flow yield of about 6.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
23.08x
P/S
0.7x
P/B
2.73x
EV / EBITDA
10.59x
HSIC trades at 23.1x trailing earnings (about 22.4x on estimated forward earnings), 0.7x sales, and 2.7x book value. Reverse-engineering today's price implies the market expects roughly 2.5% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How HSIC stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), HSIC ranks #43 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (23.1x P/E vs. 25.4x median) with a lower return on equity (11.9% vs. 14.9%) and slower revenue growth (5.6% vs. 7.9%).
P/E vs sector
23.1x
median 25.4x
ROE vs sector
11.9%
median 14.9%
Growth vs sector
5.6%
median 7.9%
Sector rank
#43
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$65.05 – $106.87
vs. $78.67 today · expected CAGR -4% – 6%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $13.98B | $14.81B | $15.70B | $16.64B | $17.64B |
| Net income | $419.25M | $444.41M | $471.07M | $499.33M | $529.29M |
| EPS | $3.68 | $3.90 | $4.14 | $4.38 | $4.65 |
| Share price (low) | $51.52 | $54.62 | $57.89 | $61.37 | $65.05 |
| Share price (high) | $84.65 | $89.73 | $95.11 | $100.82 | $106.87 |
| CAGR (low–high) | -35% / 8% | -17% / 7% | -10% / 7% | -6% / 6% | -4% / 6% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for HSIC:
- Healthy free-cash-flow yield (~6.3%) funds buybacks and dividends.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against HSIC:
- Thin net margins (3.0%) leave little room for error.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Margin risk — thin profitability (3.0%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Henry Schein is a mid-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 23.1x earnings, which our model scores Neutral (46/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.